01Core principlesThe concepts and mechanisms needed to understand the subject.
A drug interaction occurs when another exposure changes a medicine’s effects. The second exposure may be another drug, a food, an herbal preparation, smoking or a disease-related physiological change. Interactions can increase toxicity, reduce efficacy or occasionally be used intentionally. Their clinical significance depends on more than whether two names appear together in a database. Dose, timing, duration, organ function, therapeutic margin and the consequences of treatment failure determine the practical risk. A small concentration change may be unimportant for one medicine and dangerous for another with a narrow margin between benefit and harm.
The central task is to translate a mechanism into a decision. First identify the affected medicine and the direction of change; then ask what harm or failure might follow, how quickly it could emerge and whether it can be detected before serious damage occurs. Avoidance is appropriate for some combinations, whereas others can be used with an adjusted regimen and a credible monitoring plan. The decision should consider the indication for both drugs. Stopping an essential treatment to preserve a low-value one is poor prioritisation. Electronic systems support detection, but their alerts do not know every relevant feature of the patient’s current situation.
Key points
- Check interactions when medicines are started, stopped, restarted or switched between formulations and routes.
- Pharmacokinetic interactions alter exposure; pharmacodynamic interactions change combined effects without requiring a concentration change.
- An interaction alert becomes useful only when its consequence, timing and management are understood.
- Clarithromycin and simvastatin must not be given together; choose an appropriate antibiotic alternative or a documented statin interruption.
- Avoid trimethoprim or co-trimoxazole with methotrexate because severe marrow suppression can result.
- If monitoring is the chosen response, specify the parameter, timing, responsible clinician and action threshold.
02Mechanisms and patternsImportant relationships and how to distinguish them.
One product may bind another in the gastrointestinal tract, change its local environment or interfere with delivery through a feeding tube. The absorbed amount may fall despite a correctly prescribed dose. Dose separation sometimes helps, but the required interval is drug-specific; it is not a universal remedy for every interaction and does not reverse effects mediated through metabolism.
Inhibition reduces an enzyme or transporter’s activity and can increase exposure to a substrate. Induction increases the system’s capacity and may reduce exposure. Changes need not be immediate or end with the last dose of the interacting medicine. Stopping an inducer can increase concentrations of a drug whose dose was previously raised to compensate.
Medicines that alter renal perfusion, tubular handling or fluid balance can change elimination of another drug. A new interaction can therefore emerge during dehydration without any increase in prescribed dose. Interpret kidney function alongside current intake and urine output; a reassuring historical result does not protect against a new reduction in clearance.
Two agents may independently impair haemostasis, slow heart rate, prolong repolarisation or depress the central nervous system. Their combined effect can be harmful even when each concentration is in its usual range. This explains why a normal drug level may fail to exclude a clinically important pharmacodynamic interaction.
03Interpreting evidenceInformation, measurements and their limitations.
Consider the information, its meaning and its limitations before deciding what follows.
- 01
Complete exposure map - Why
- Identify every drug and non-prescription factor that could participate.
- Interpretation and limitations
- Include intermittent analgesics, supplements, short antibiotic courses, recent discontinuations and changes in smoking. Establish actual start and stop dates. A prescription record alone may miss the newly purchased product that explains why previously tolerated treatment has become problematic.
- 02
Pair-specific interaction assessment - Why
- Determine mechanism, severity and the recommended management for this combination.
- Interpretation and limitations
- Use the exact medicines and formulation, read the full interaction advice and compare it with product information. An alert category is a starting point. Distinguish a contraindication from a precaution and check whether any suggested dose adjustment applies to the patient’s indication.
- 03
Targeted toxicity measurements - Why
- Look for the predicted consequence before it becomes clinically severe.
- Interpretation and limitations
- For suspected muscle injury obtain creatine kinase and assess kidney function; for arrhythmic risk consider ECG and electrolytes; for marrow toxicity obtain a blood count. Tests should follow the mechanism and symptoms. A normal baseline demonstrates a starting position rather than proving that a future combination is safe.
- 04
Treatment-effect assessment - Why
- Identify interactions that cause under-treatment rather than obvious toxicity.
- Interpretation and limitations
- Check recurrence of the treated disorder, relevant physiological markers and adherence before increasing the dose. If exposure has been reduced by an interacting agent, compensatory escalation can become unsafe when that agent is subsequently stopped. The future withdrawal plan belongs in the current prescribing decision.
04Applied reasoningWorked examples connecting principles to decisions.
01Worked caseHandle a contraindicated temporary combinationA 63-year-old taking simvastatin 40 mg nightly is prescribed clarithromycin for an infection. He has not started the antibiotic and reports no muscle symptoms. The antibiotic prescriber has not seen his repeat list.+
- 1Confirm the infection assessment, the precise antibiotic indication and the current statin exposure. There is time to prevent the interaction because the new treatment has not started; do not tell the person simply to watch for symptoms while taking both.
- 2Recognise potent inhibition of simvastatin metabolism and the resulting muscle-toxicity risk. The combination is contraindicated. Separating the doses between morning and evening will not resolve enzyme inhibition.
- 3Contact the treating clinician to choose an effective, clinically appropriate non-interacting antibiotic if possible. If clarithromycin is necessary, arrange a documented temporary suspension of simvastatin during the course rather than an unplanned dose reduction.
- 4Tell the person exactly which medicine to take, which to pause and when the long-term treatment will be reviewed or resumed. Check that the amended instructions reach the dispensing team and are not contradicted by the printed repeat label.
- 5Verify that no doses of the combination were taken and ask about muscle pain, weakness or dark urine. If exposure and symptoms emerge, arrange prompt clinical and laboratory assessment. Ensure the temporary interruption does not become permanent loss of indicated lipid treatment.
02Risk modificationUse a monitored combination only when justifiedBoth treatments provide meaningful benefit and the pair is not contraindicated, but their combined risk requires a deliberate plan.+
- 1Compare substitution with dose adjustment and monitoring. Prefer a change that removes an avoidable risk while preserving the main therapeutic goals. A theoretically monitorable interaction may still be unsuitable when timely tests or follow-up are unavailable.
- 2Assess patient-specific amplifiers such as renal impairment, older age, falls, previous bleeding or several additional sedating medicines. A database’s average description may understate the risk in a person with multiple vulnerabilities.
- 3Specify what monitoring can detect and what it cannot. For a DOAC plus an NSAID, bleeding risk is not safely quantified by a routine INR; consider a different analgesic and minimise avoidable exposure rather than creating false reassurance with the wrong test.
- 4Record the rationale, review time and symptoms requiring help. Revisit the plan when either dose changes, acute illness develops or one component is withdrawn. A combination tolerated at one stage may require a different response later.
03High-consequence pairsRecognise mechanisms that warrant early escalationA review identifies a medicine with a narrow safety margin or two treatments with overlapping serious toxicity.+
- 1For low-dose methotrexate, avoid trimethoprim and co-trimoxazole because combined antifolate effects can cause severe marrow suppression. If exposure has occurred, seek specialist advice, assess symptoms and arrange the monitoring required for the exposure and clinical state.
- 2For medicines with QT effects, inspect the complete combination and correct relevant electrolyte abnormalities. Citalopram and escitalopram have specific restrictions, including contraindicated co-administration with other QT-prolonging medicines; monitoring does not automatically override such a restriction.
- 3When an anticoagulant is involved, consider both bleeding and loss of anticoagulant effect. A strong inducer may reduce protection while an inhibitor or added antiplatelet effect may increase bleeding; the direction of the interaction determines the response.
- 4Escalate uncertain high-risk combinations to a pharmacist or relevant specialist before further exposure when feasible. Provide the exact doses, indication, start dates, renal function and proposed alternatives so advice can resolve the clinical decision.
05Relevant medicines and safetySpecific regimens and precautions where medicines are relevant.
Simvastatin with amlodipine: restricted continuation
If simvastatin remains appropriate with amlodipine, give no more than 20 mg orally once daily in the evening; continue long term only with an agreed lipid-treatment review.A dose ceiling does not authorise use with contraindicated strong CYP3A4 inhibitors such as clarithromycin. Review efficacy and consider a suitable alternative statin when more lipid lowering is needed.
06Checking understandingVerify the reasoning, revisit uncertainties and apply feedback.
- Link surveillance to onset and offset. A short antibiotic course can require action on a long-term medicine, while an enzyme effect can persist beyond the final interacting dose. Record a drug-specific restart plan where relevant.
- Ask about symptoms that match the suspected mechanism, such as bruising, black stools, excessive sedation or muscle weakness. Non-specific reassurance about side effects is less useful than a small number of recognisable warning features.
- If a dose was changed to compensate for an interaction, review it when the interacting exposure ends. Otherwise a rational temporary adjustment may become the next prescribing error.
- Use repeat clinical and laboratory assessment to establish whether the chosen mitigation works. Check that tests were performed at interpretable times and that the person could follow the altered schedule.
07Special situationsVariants, exceptions and circumstances that change the usual approach.
Stopping is an intervention
Medicine withdrawal changes an interaction network. Removing an inhibitor can reduce another medicine’s exposure; removing an inducer can increase it. A discontinuation deserves the same interaction check as a new prescription, especially after compensatory dose changes.
Interaction does not mean incompatibility
Some combinations are deliberately used for additive benefit. The question is whether the expected advantage outweighs harm with the available safeguards. Document the intended purpose so a future reviewer understands why an alert was accepted.
A level can mislead
A measured concentration describes a sample at a particular time. It may not reflect a previous toxic peak, tissue sensitivity or an additive pharmacodynamic effect. Interpret it with symptoms, sampling time, recent doses and the known mechanism.
Precision improves consultation
Asking whether two drug classes interact can produce a broad answer that misses the actual problem. Give exact molecules, doses and duration. Closely related products can differ in metabolic pathways, transport and the practical options for managing risk.
08Common pitfallsFrequent interpretation and management errors.
- 01
Assuming a small temporal separation solves a metabolic interaction confuses altered absorption with inhibition that persists throughout the dosing interval.
- 02
Overriding repeated alerts without reading the management recommendation risks missing the one contraindicated combination among many lower-impact warnings.
- 03
Focusing only on toxicity misses loss of efficacy, including failure of anticoagulation or recurrence of disease after reduced drug exposure.
- 04
Leaving a paused medicine without a restart or reassessment date can convert temporary risk reduction into avoidable long-term under-treatment.